201 related articles for article (PubMed ID: 32831069)
1. Short-course Benznidazole treatment to reduce Trypanosoma cruzi parasitic load in women of reproductive age (BETTY): a non-inferiority randomized controlled trial study protocol.
Cafferata ML; Toscani MA; Althabe F; Belizán JM; Bergel E; Berrueta M; Capparelli EV; Ciganda Á; Danesi E; Dumonteil E; Gibbons L; Gulayin PE; Herrera C; Momper JD; Rossi S; Shaffer JG; Schijman AG; Sosa-Estani S; Stella CB; Klein K; Buekens P
Reprod Health; 2020 Aug; 17(1):128. PubMed ID: 32831069
[TBL] [Abstract][Full Text] [Related]
2. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial.
Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y
Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503
[TBL] [Abstract][Full Text] [Related]
3. Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: A systematic review and meta-analysis.
Ciapponi A; Barreira F; Perelli L; Bardach A; Gascón J; Molina I; Morillo C; Prado N; Riarte A; Torrico F; Ribeiro I; Villar JC; Sosa-Estani S
PLoS Negl Trop Dis; 2020 Aug; 14(8):e0008529. PubMed ID: 32804966
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial.
Molina-Morant D; Fernández ML; Bosch-Nicolau P; Sulleiro E; Bangher M; Salvador F; Sanchez-Montalva A; Ribeiro ALP; de Paula AMB; Eloi S; Correa-Oliveira R; Villar JC; Sosa-Estani S; Molina I
Trials; 2020 Apr; 21(1):328. PubMed ID: 32293523
[TBL] [Abstract][Full Text] [Related]
5. Towards the establishment of a consensus real-time qPCR to monitor Trypanosoma cruzi parasitemia in patients with chronic Chagas disease cardiomyopathy: a substudy from the BENEFIT trial.
Moreira OC; Ramírez JD; Velázquez E; Melo MF; Lima-Ferreira C; Guhl F; Sosa-Estani S; Marin-Neto JA; Morillo CA; Britto C
Acta Trop; 2013 Jan; 125(1):23-31. PubMed ID: 22982466
[TBL] [Abstract][Full Text] [Related]
6. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial.
Torrico F; Gascon J; Ortiz L; Alonso-Vega C; Pinazo MJ; Schijman A; Almeida IC; Alves F; Strub-Wourgaft N; Ribeiro I;
Lancet Infect Dis; 2018 Apr; 18(4):419-430. PubMed ID: 29352704
[TBL] [Abstract][Full Text] [Related]
7. Clomipramine and benznidazole association for the treatment of acute experimental Trypanosoma cruzi infection.
Strauss M; Lo Presti MS; Bazán PC; Baez A; Fauro R; Esteves B; Sanchez Negrete O; Cremonezzi D; Paglini-Oliva PA; Rivarola HW
Parasitol Int; 2013 Jun; 62(3):293-9. PubMed ID: 23500720
[TBL] [Abstract][Full Text] [Related]
8. Drug Repurposing in Chagas Disease: Chloroquine Potentiates Benznidazole Activity against Trypanosoma cruzi
Pandey RP; Nascimento MS; Franco CH; Bortoluci K; Silva MN; Zingales B; Gibaldi D; Castaño Barrios L; Lannes-Vieira J; Cariste LM; Vasconcelos JR; Moraes CB; Freitas-Junior LH; Kalil J; Alcântara L; Cunha-Neto E
Antimicrob Agents Chemother; 2022 Nov; 66(11):e0028422. PubMed ID: 36314800
[TBL] [Abstract][Full Text] [Related]
9. Nanoencapsulation of benznidazole in calcium carbonate increases its selectivity to Trypanosoma cruzi.
Tessarolo LD; de Menezes RRPPB; Mello CP; Lima DB; Magalhães EP; Bezerra EM; Sales FAM; Barroso Neto IL; Oliveira MF; Dos Santos RP; Albuquerque EL; Freire VN; Martins AM
Parasitology; 2018 Aug; 145(9):1191-1198. PubMed ID: 29642963
[TBL] [Abstract][Full Text] [Related]
10. A novel antibody surrogate biomarker to monitor parasite persistence in Trypanosoma cruzi-infected patients.
Zrein M; Granjon E; Gueyffier L; Caillaudeau J; Liehl P; Pottel H; Cardoso CS; Oliveira CDL; de Oliveira LC; Lee TH; Ferreira AM; Ribeiro ALP; Busch MP; Sabino EC
PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006226. PubMed ID: 29425201
[TBL] [Abstract][Full Text] [Related]
11. A clinical adverse drug reaction prediction model for patients with chagas disease treated with benznidazole.
Sperandio da Silva GM; Mediano MF; Alvarenga Americano do Brasil PE; da Costa Chambela M; da Silva JA; de Sousa AS; Xavier SS; Rodrigues da Costa A; Magalhães Saraiva R; Hasslocher-Moreno AM
Antimicrob Agents Chemother; 2014 Nov; 58(11):6371-7. PubMed ID: 25114135
[TBL] [Abstract][Full Text] [Related]
12. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.
Morillo CA; Waskin H; Sosa-Estani S; Del Carmen Bangher M; Cuneo C; Milesi R; Mallagray M; Apt W; Beloscar J; Gascon J; Molina I; Echeverria LE; Colombo H; Perez-Molina JA; Wyss F; Meeks B; Bonilla LR; Gao P; Wei B; McCarthy M; Yusuf S;
J Am Coll Cardiol; 2017 Feb; 69(8):939-947. PubMed ID: 28231946
[TBL] [Abstract][Full Text] [Related]
13. Prevention of congenital Chagas disease by Benznidazole treatment in reproductive-age women. An observational study.
Álvarez MG; Vigliano C; Lococo B; Bertocchi G; Viotti R
Acta Trop; 2017 Oct; 174():149-152. PubMed ID: 28720492
[TBL] [Abstract][Full Text] [Related]
14. Chagas disease and liver transplantation: Experience in Argentina using real-time quantitative PCR for early detection and treatment.
Balderramo D; Bonisconti F; Alcaraz A; Giordano E; Sánchez A; Barrabino M; Caeiro JP; Alvarellos T; Maraschio M
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28941300
[TBL] [Abstract][Full Text] [Related]
15. Benznidazole treatment in chronic children infected with Trypanosoma cruzi: serological and molecular follow-up of patients and identification of Discrete Typing Units.
Rumi MM; Pérez Brandán C; Gil JF; D'Amato AM; Ragone PG; Lauthier JJ; Tomasini N; Cimino RO; Orellana V; Lacunza CD; Nasser JR; Basombrío MA; Diosque P
Acta Trop; 2013 Oct; 128(1):130-6. PubMed ID: 23880286
[TBL] [Abstract][Full Text] [Related]
16. Essential oils from Syzygium aromaticum and Zingiber officinale, administered alone or in combination with benznidazole, reduce the parasite load in mice orally inoculated with Trypanosoma cruzi II.
Sarto MPM; Lucas da Silva HF; de Souza Fernandes N; de Abreu AP; Zanusso Junior G; de Ornelas Toledo MJ
BMC Complement Med Ther; 2021 Feb; 21(1):77. PubMed ID: 33632196
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of Serial Blood Sampling and PCR Replicates for Treatment Monitoring of Patients with Chronic Chagas Disease.
Parrado R; Ramirez JC; de la Barra A; Alonso-Vega C; Juiz N; Ortiz L; Illanes D; Torrico F; Gascon J; Alves F; Flevaud L; Garcia L; Schijman AG; Ribeiro I
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509941
[TBL] [Abstract][Full Text] [Related]
18. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.
de Andrade AL; Zicker F; de Oliveira RM; Almeida Silva S; Luquetti A; Travassos LR; Almeida IC; de Andrade SS; de Andrade JG; Martelli CM
Lancet; 1996 Nov; 348(9039):1407-13. PubMed ID: 8937280
[TBL] [Abstract][Full Text] [Related]
19. HIV and Chagas Disease: An Evaluation of the Use of Real-Time Quantitative Polymerase Chain Reaction to Measure Levels of Trypanosoma cruzi Parasitemia in HIV Patients in Cochabamba, Bolivia.
Reimer-McAtee MJ; Mejia C; Clark T; Terle J; Pajuelo MJ; Cabeza J; Lora MH; Valencia E; Castro R; Lozano D; Bern C; Torrico F; Gilman RH
Am J Trop Med Hyg; 2021 Aug; 105(3):643-650. PubMed ID: 34398818
[TBL] [Abstract][Full Text] [Related]
20. Role of nucleic acid amplification assays in monitoring treatment response in chagas disease: Usefulness in clinical trials.
Sulleiro E; Muñoz-Calderon A; Schijman AG
Acta Trop; 2019 Nov; 199():105120. PubMed ID: 31376368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
